I Taylor

ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.

Taavi K. Neklesa, Lawrence B. Snyder, Ryan R. Willard et al. · Journal of Clinical Oncology · 2019 · 207 citations

Medicine, Oncology, Pharmacology +16

First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).

Daniel P. Petrylak, Xīn Gào, Nicholas J. Vogelzang et al. · Journal of Clinical Oncology · 2020 · 165 citations

Medicine, Oncology, Pharmacology +16

Laser therapy for breast cancer: MR imaging and histopathologic correlation.

Hamid Mumtaz, Margaret Hall‐Craggs, AC Wotherspoon et al. · Radiology · 1996 · 151 citations

Medicine, Oncology, Radiology +17

Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer

JJ Flanagan, Yimin Qian, SM Gough et al. · Cancer Research · 2019 · 133 citations

Medicine, Biochemistry, Endocrinology +16

Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer

Lawrence B. Snyder, John J. Flanagan, Yimin Qian et al. · Cancer Research · 2021 · 110 citations

Life Sciences, Biochemistry, Endocrinology +15